Secondary rituximab‐associated versus primary immunodeficiencies: The enigmatic border
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Immunology"
DOI: 10.1002/eji.202149667
Abstract: Rituximab (RTX), a chimeric monoclonal antibody targeting CD20‐positive cells, is a valuable treatment option for malignant and benign immune‐related disorders. The rationale of targeting the CD20 antigen relies on depletion of both healthy and autoreactive/malignant… read more here.
Keywords: cell; rtx; secondary rituximab; hypogammaglobulinemia ... See more keywords